The abstract is read at the publisher; the summary is JClub's.
DEGS1 expression in glioblastoma is linked to aggressive biomarkers and worse patient survival, and DEGS1 is required for glioma growth across patient-derived cells, Drosophila, and xenograft mice.
- Why it matters: IGF signaling drives glioblastoma progression, but how sphingolipid metabolism regulates tumor growth and therapy response is unclear, limiting targeted metabolic interventions.
- What they did: Bioinformatic analyses identified sphingolipid metabolism genes, and functional tests using patient-derived cells, a Drosophila glioma model, and xenograft mouse models focused on DEGS1; lipidomics and RNA sequencing mapped mechanism, and a DEGS1 inhibitor was tested against IGF1R-targeted therapy.
- The result: DEGS1 deficiency reduced ceramides and complex sphingolipids while accumulating precursors, disrupted lipid raft biogenesis, impaired lipid raft-associated IGF signaling, and decreased GBM cell growth and resistance to IGF1R inhibition.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.